Patents Issued in October 6, 2020
  • Methods for treatment of bladder dysfunction
    Patent number: 10792320
    Abstract: A nutritional supplement and method of treating or preventing urogenital system disorders including urinary incontinence, overactive bladder, enuresis, benign prostatic hyperplasia, nocturia, cystitis, and urinary calculi, without unwanted side effects. The supplement comprises vitamin D3, nitric oxide precursor, pumpkin seed extract and prebiotic fiber in a particular composition.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: October 6, 2020
    Inventor: Michael Alan Beller
  • Massage and sport cream composition systems
    Patent number: 10792321
    Abstract: A cream composition for massage and sport is disclosed herein. The cream composition includes ricinus communis (castor) seeds oil, sesamum indicum (sesame) seeds oil, deionized water, isopropyl myristate, triticum vulgare (wheat) germ oil, butyrospermum parkii (shea) butter, white iodine, cetostearyl alcohol, a fragrance, sodium laureth sulfate (SLES), bentonite, dmdm hydantoin, sodium chloride, benzyl alcohol, and behydroacetic acid. The composition is administered topically to assist with comforting muscular pain, increasing flexibility, and improving overall skin health.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: October 6, 2020
    Inventors: Nermeen Samir Elrayes, Samir S. H. Alrayyes, Shdia A. S. Alrayyes, Lina S. S. Alrayyes, Lana S. S. Alrayyes, Bodour Samir Shaban Alrayyes, Bader S. S. Alrayyes, Mohammed S. S. Alrayyes, Nevin S. S. Doshan
  • Herbal compositions and methods for the prevention and treatment of plant of nail infections
    Patent number: 10792322
    Abstract: It is disclosed a pharmaceutical and/or phytosanitary composition comprising an aqueous extract of Chelidonium majus root and an acceptable pharmaceutical or phytosanitary excipient, for the prevention or treatment of plant infections and/or for the prevention or treatment of nail 5 infections. The composition may further comprise an aqueous extract of Thuja occidentalis leaf; and from about 1 to 5% of at least one natural phenolic compound. The composition is efficient in the treatment of plant infection (mildew fungus, blight fungus, etc); the treatment of intumescence of a plant; the treatment of potatoes (powdery or common scab, Rhizoctonia, etc), and also allows a higher crop yield: without the use of a chemical fungicide. The composition also allows rapid treatment of fungus infection of nails.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: October 6, 2020
    Assignee: MONDIAS NATURAL PRODUCTS INC
    Inventors: Guy Chamberland, William Lee
  • Pharmaceutical composition for preventing or treating neurodegenerative diseases which includes flower extract of daphne genkwa or fractions thereof as active ingredient
    Patent number: 10792323
    Abstract: The present invention relates to a pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases which include a flower extract of Daphne genkwa or fractions thereof as an active ingredient. The pharmaceutical composition and health functional food for preventing or treating neurodegenerative diseases are, not like extracts from stems and/or roots of Daphne genkwa, free from genotoxicity and have superior prophylactic or treatment effects against neurodegenerative diseases.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: October 6, 2020
    Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Won Gon Kim, Baek Soo Han, Jeong Su Byun, Ha Young Choi
  • Compositions and methods for the treatment of orthopedic ailments
    Patent number: 10792324
    Abstract: A composition for enhancing treatment of orthopedic ailments stimulates iNOS and enhances treatment of orthopedic ailments when a pharmaceutically effective amount is administered over a sufficient period of time. The composition comprises ginger, Muira puama, Paullinia cupana, and at least one of the group consisting of L-arginine and L-citrulline.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: October 6, 2020
    Assignee: K.L.R.M., LLC
    Inventors: Jacob Rajfer, Rebecca Rajfer
  • Pharmaceutical formulation for bedwetting and method of use thereof
    Patent number: 10792326
    Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: October 6, 2020
    Assignee: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Supramolecular gylcosaminoglycans
    Patent number: 10792327
    Abstract: Provided herein are glycosylated peptide amphiphiles (GPAs), supramolecular glyconanostructures assembled therefrom, and methods of use thereof. In particular, provided herein are glycosaminoglycan (GAG) mimetic peptide amphiphiles (PAs) and supramolecular GAG mimetic nanostructures assembled therefrom that mimic the biological activities of GAGs, such as heparin, heparan sulfate, hyaluronic acid etc.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: October 6, 2020
    Assignee: Northwestern University
    Inventors: Samuel I. Stupp, Bo Timmy Bjorn Fyrner, Sung Soo Lee
  • Nanocomplexes for delivery of saporin
    Patent number: 10792328
    Abstract: A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: October 6, 2020
    Assignee: Trustees of Tufts College
    Inventors: Qiaobing Xu, Ming Wang
  • S100 based treatment of cardiac power failure
    Patent number: 10792329
    Abstract: The present invention relates to S100 protein and nuclei acids encoding S100 protein for enhancing the cardiac power as well as vectors and pharmaceuticals comprising the same and uses thereof.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: October 6, 2020
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Hugo Katus, Patrick Most
  • Treatment with methylation-controlled J protein (MCJ)
    Patent number: 10792330
    Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 6, 2020
    Assignee: University of Vermont and State Agricultural College
    Inventors: Mercedes Rincon, Ketki M. Hatle
  • Methods for reducing cardiotoxicity from chemotherapy by administering humanin analog compositions
    Patent number: 10792331
    Abstract: Provided herein are compositions, methods and uses of humanin or a humanin analog, for example, in treating a subject with humanin or a humanin analog, in part, to reduce, decrease, or inhibit cardiotoxicity caused or induced by an anti-cancer or anti-tumor therapeutic agent, or to protect or preserve cardiac function in the presence of an anti-tumor or anti-cancer therapeutic agent. In some aspects, humanin or humanin analogs, alone or in combination with another cardioprotective agent such as Dexrazoxane are used in combination with a chemotherapeutic agent to treat a hyperproliferative disease or disorder.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: October 6, 2020
    Assignee: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Christina Wang, YanHe Lue, Ronald S. Swerdloff
  • Anti-infective properties of antifreeze protein
    Patent number: 10792332
    Abstract: As microbial drug-resistance increases, there is a critical need for new classes of compounds to combat infectious diseases. The Ixodes scapularis tick antifreeze glycoprotein, IAFGP, functions as an anti-infective agent against diverse bacteria including methicillin-resistant Staphylococcus aureus. Recombinant IAFGP and a peptide, P1, described herein and derived from this protein, bind to microbes and alter biofilm formation. Transgenic iafgp-expressing flies and mice challenged with bacteria, as well as wild-type animals administered IAFGP or P1, were resistant to infection, septic shock, or biofilm development on implanted biomaterials. Antifreeze protein controls bacterial infection and present new therapeutic strategies to counter pathogens.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: October 6, 2020
    Assignees: Yale University, Howard Hughes Medical Institute
    Inventors: Erol Fikrig, Martin Heisig, Nabil Abraham, Girish Neelakanta
  • Peptides derived from actin-like protein 8 (ACTL8)
    Patent number: 10792333
    Abstract: The present invention relates to novel peptides derived from Actin-like protein 8 (ACTL8), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: October 6, 2020
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Alina Popa, Philip Addis
  • Stable liquid gonadotropin formulation
    Patent number: 10792334
    Abstract: The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: October 6, 2020
    Assignee: Ferring B.V.
    Inventors: Helen Ulrika Sjögren, Charlotte Højer-Pedersen
  • Rapid-acting insulin composition comprising a substituted citrate
    Patent number: 10792335
    Abstract: A composition, in the form of an aqueous solution, including an insulin in hexameric form and at least one substituted citrate of formula I: in which: R1, R2, R3, identical or different, represent OH or AA, at least one of the R1, R2, R3 is an AA radical, AA is a radical resulting from a natural or synthetic aromatic amino acid comprising at least one phenyl group or indole group, substituted or not substituted, said AA radical having at least one free carboxylic acid function, and the carboxylic acid functions are in the form of a salt of an alkali metal selected from Na+ and K+.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: October 6, 2020
    Assignee: ADOCIA
    Inventors: Olivier Soula, Richard Charvet, Bertrand Alluis
  • Method of treating hemophilia A
    Patent number: 10792336
    Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a Factor VIII protein, wherein a B domain portion of the Factor VIII protein is encoded by a nucleotide sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a Factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: October 6, 2020
    Assignees: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, UCL BUSINESS LTD
    Inventors: Amit Nathwani, Jenny McIntosh, Edward Tuddenham, Andrew Davidoff
  • Wound healing compositions
    Patent number: 10792337
    Abstract: Provided herein are biologically active solution compositions comprising one or more sacrificial proteolytic enzyme substrates, one or more preservatives, and one or more antimicrobial agents and methods of using the solution compositions to treat tissue sites, in particular chronic wounds. The compositions may be used in conjunction with negative pressure wound therapy to treat tissue sites.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 6, 2020
    Assignee: KCI Licensing, Inc.
    Inventors: Braden King-Fung Leung, Ona Whelove, Chester R. Edlund, John R. Harper
  • Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
    Patent number: 10792338
    Abstract: A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythropoietin and about 100-300 mg per cm2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: October 6, 2020
    Assignee: Remedor Biomed Ltd.
    Inventor: Saher Hamed
  • Methods and compositions for treating phenylketonuria
    Patent number: 10792339
    Abstract: The present invention provides compositions and methods of treating hyperphenylalaninemia (e.g., phenylketonuria) in a subject in need thereof comprising administering to the subject an effective amount of a phenylalanine dehydrogenase (PheDH) polypeptide. The present invention also provides pharmaceutical formulations comprising PheDH for lowering the phenylalanine concentration in the subject (e.g., in the intestines and/or blood).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 6, 2020
    Assignee: CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Marshall Summar, Juan Cabrera-Luque, Gary Cunningham, Dione T. Kobayashi, James G. McArthur
  • Antibacterial composition for combating carbapenem-resistant gram-negative bacteria comprising ADK protein as active ingredient
    Patent number: 10792340
    Abstract: Provided is an antibacterial composition against carbapenem-resistant gram-negative bacteria which includes, as an active ingredient, adenylate kinase (ADK) protein derived from Mycobacterium tuberculosis. The ADK protein derived from Mycobacterium tuberculosis, according to the subject matter, has excellent antimicrobial activity against carbapenem-resistant gram-negative bacteria, and thus may be usefully used in a variety of fields as an antibacterial composition.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: October 6, 2020
    Assignee: KONKUK UNIVERSITY GLOCAL INDUSTRY-ACADEMIC COLLABORATION FOUNDATION
    Inventors: Yeong Min Park, In Duk Jung, Seung Jun Lee
  • Treatment of glycogen storage disease type II
    Patent number: 10792341
    Abstract: Methods of treating glycogen storage disease type II, by administering acid ?-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Duke University
    Inventor: Yuan-Tsong Chen
  • Targeting of glycoprotein therapeutics
    Patent number: 10792342
    Abstract: Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: October 6, 2020
    Assignee: Genzyme Corporation
    Inventor: James Stefano
  • Compositions and methods for treating MPSI
    Patent number: 10792343
    Abstract: A vector have an expression cassette containing have a hIDUA gene has a sequence of SEQ ID NO: 1 (FIG. 1) or a sequence at least about 95% identical thereto which encodes a functional human alpha-L-iduronidase is provided. The vector may be a production vector or a rAAV8. Also provided are compositions containing these vectors and methods of treating MPSI and the symptoms associated with Hurler, Hurler-Scheie and Scheie syndromes.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: October 6, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Brittney L. Gurda
  • High frequency application of botulinum toxin therapy
    Patent number: 10792344
    Abstract: The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and/or in high doses.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: October 6, 2020
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Matthias Marx, Susanne Grafe, Reiner Benecke, Dirk Dressler
  • Dermal filler
    Patent number: 10792345
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 6, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
    Patent number: 10792346
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: October 6, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly, Vincent John Wacher
  • Methods for diagnosing and treating Alzheimer's disease
    Patent number: 10792347
    Abstract: Methods for diagnosing and treating Alzheimer's disease are provided. In particular, methods of restoring blood-brain barrier integrity and/or promoting vascular reversion in a person suffering from Alzheimer's disease by administering an anti-angiogenic agent or an agent that is capable of restoring tight junction integrity. Methods of preventing or delaying the onset of Alzheimer's disease in a subject are also provided.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: October 6, 2020
    Assignee: Alternative Extracts Inc.
    Inventors: Wilfred Jefferies, Kaan E. Biron, Dara L. Dickstein
  • Enhancing T cell activation using altered MHC-peptide ligands
    Patent number: 10792348
    Abstract: Materials and methods for identifying and using MEW molecule variants for activating self-reactive T cells in a peptide-specific manner, and their use to focus autoimmune cellular responses against diseases such as cancers and persisting viral infections, are described.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: October 6, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Larry R. Pease
  • Galectin-3 as immunological target
    Patent number: 10792349
    Abstract: Compositions for the treatment of cancer include an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting tumor cell vaccine and an anti-galectin-3 antibody. Increased titers of anti-galectin-3 antibodies were correlated with clinical outcome.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: October 6, 2020
    Assignee: The Johns Hopkins University
    Inventors: Elizabeth Marion Jaffee, Lanqing Huang, Lei Zheng
  • Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
    Patent number: 10792350
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: October 6, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
  • Compositions and methods of enhancing immune responses to or limiting infection
    Patent number: 10792351
    Abstract: Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: October 6, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: John R. Barta, Luc Berghman, Srichaitanya Shivaramaiah, Olivia B. Faulkner, Lisa Bielke, Billy Hargis
  • Method for reducing skatole and/or indole in animals
    Patent number: 10792352
    Abstract: The present invention relates i.a. to a method for reducing the concentration of skatole and/or indole in an animal comprising administering to said animal an effective amount of an immunogenic composition comprising Lawsonia intracellularis antigen. Therefore, the present invention also relates to methods for reducing pork odor or boar taint.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: October 6, 2020
    Inventors: Ryouichi Moki, Eigo Sakamoto, Takeshi Yamaguchi
  • Virus like particle purification
    Patent number: 10792353
    Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 6, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
  • Feed additive composition for immunoprotection of fish against infectious viral species
    Patent number: 10792354
    Abstract: An oral vaccine composition for fish, and related oral vaccine delivery system and methods for making and using such oral vaccine composition and delivery system are described. The oral vaccine composition includes virus-like particles effective to mediate an immunoprotective response in a target fish species, wherein the virus-like particles are contained in biomass of an organism or cell culture in which the virus-like particles have been expressed, optionally further including (i) adjuvant effective to enhance the immunoprotective response of the virus-like particles in the target fish species; (ii) encapsulant protectively associated with the virus-like particles for selective locus bioavailability in the target fish species; and/or (iii) binding agent aggregating the ingredients of the composition with one another.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: October 6, 2020
    Assignees: UNIVERSITY OF MARYLAND BALTIMORE COUNTY, ALLOTROPIC TECH, LLC
    Inventors: Vikram N. Vakharia, Robert Balcerzak
  • Method for purifying and concentrating inactivated antigen of foot-and-mouth disease virus
    Patent number: 10792355
    Abstract: A method for inactivated foot-and-mouth disease virus antigen purification and concentration, which relates to the field of biotechnology which includes the following steps of: (1) adding an adaptor protein with an amino acid sequence as shown in SEQ ID NO: 2 into the inactivated foot-and-mouth disease virus antigen, mixing evenly, and incubating; (2) adding a purified carrier, mixing evenly, and incubating the mixture, the purified carrier being a Lactococcus lactis skeleton; and (3) centrifuging and obtaining a precipitate.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: October 6, 2020
    Assignee: JIANGSU ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Xuwen Qiao, Qisheng Zheng, Xiaoming Yu, Jin Chen, Pengcheng Li, Yuanpeng Zhang, Liting Hou, Jibo Hou
  • Recombinant RSV with silent mutations, vaccines, and methods related thereto
    Patent number: 10792356
    Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 6, 2020
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher C. Stobart
  • Optimized HIV envelope gene and expression thereof
    Patent number: 10792357
    Abstract: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: October 6, 2020
    Assignee: INTERNATIONAL AIDS VACCINE INITIATIVE
    Inventors: Christopher L. Parks, Maoli Yuan, Xinsheng Zhang, Aaron Wilson, Angela Grazia Lombardo, Eddy Sayeed, Josephine Helena Cox, Takashi Hironaka, Makoto Inoue, Hiroto Hara
  • ISG15 and its use as an adjuvant
    Patent number: 10792358
    Abstract: Disclosed herein is a vaccine comprising an antigen and ISG15. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating a subject in need thereof. The methods may comprise administering the vaccine to the subject.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 6, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David Weiner, Daniel Villarreal
  • Methods of using a vaccine composition containing synthetic adjuvant
    Patent number: 10792359
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
    Patent number: 10792360
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-TNF? antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-TNF? antibody.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: October 6, 2020
    Assignee: ChemoCentryx, Inc.
    Inventors: Thomas Schall, James J. Campbell
  • Lipids and lipid compositions for the delivery of active agents
    Patent number: 10792361
    Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: October 6, 2020
    Assignee: NOVARTIS AG
    Inventors: Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
  • Compositions and methods for efficient delivery of molecules to cells
    Patent number: 10792362
    Abstract: The present invention provides lipid aggregate compositions having at least two cationic lipids in combination with one or optionally more than one non-cationic lipids for the in vitro and/or in vivo delivery of biologically active molecules including nucleic acids, specifically DNA and RNA, and proteins into cells and tissues. Methods are also provided that use the compounds of the present invention to deliver biologically active molecules, into cells and tissues to facilitate the expression of target proteins therein. In some non-limiting embodiments, the subject lipid aggregate compositions can be used to deliver nucleic acid molecules to facilitate the expression of proteins involved in cellular reprogramming and genome editing applications.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 6, 2020
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Xavier de Mollerat du Jeu, Nektaria Andronikou
  • Anhydrous sodium thiosulfate and formulations thereof
    Patent number: 10792363
    Abstract: Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: October 6, 2020
    Assignee: FENNEC PHARMACEUTICALS, INC.
    Inventors: Thomas Claiborne Lovelace, Joseph Alexander Moore, III, Christopher McKinnon Lee, Daniel Logan Kirschner
  • Tamper resistant pharmaceutical formulations
    Patent number: 10792364
    Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: October 6, 2020
    Assignee: PURDUE PHARMA L.P.
    Inventors: Debora Guido, Haiyong Hugh Huang
  • Peptide derivative and use thereof
    Patent number: 10792365
    Abstract: A peptide derivative represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents an oxygen atom or NR, Y represents NH2, N(Me)H, SH, OH, or phenyl in which any one of hydrogen atoms is replaced by NH2 or OH, and R represents a hydrogen atom or C1-C3 alkyl, provided that the derivative where X is NH, and Y is NH2, and the derivative where X is NH, and Y is N(Me)H are excluded.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: October 6, 2020
    Assignee: Toray Industries, Inc.
    Inventors: Yukihiro Nishio, Shinya Yokosaka
  • Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
    Patent number: 10792366
    Abstract: Provided herein are methods for reducing clearance of nanotherapeutic agents from a subject, wherein the methods comprise administering a nutrition supplement to the subject prior to administration of the nanotherapeutic agent in the treatment of a disease. Methods for improving the bioavailability of the nanotherapeutic agent, methods of reducing the toxicity of the nanotherapeutic agent, and kits comprising the nutrition supplement and nanotherapeutic agent are also provided.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: October 6, 2020
    Assignee: Carnegie Mellon University
    Inventors: Chien Ho, Li Liu, Qing Ye
  • Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid
    Patent number: 10792367
    Abstract: The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y—R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety—by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugates as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: October 6, 2020
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Michael Wagner, Thomas Olpp, Nino Meyer, Martin Bossart, Andreas Evers, Peyman Sakhaii, Pradeep K. Dhal, Paul Konowicz, James E. Stefano, Nils Poth
  • Bicyclic peptide ligands specific for MT1-MMP
    Patent number: 10792368
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: October 6, 2020
    Assignee: BicycleRD Limited
    Inventors: Daniel Paul Teufel, Catherine Lucy Stace, Silvia Pavan, Edward Walker, Leonardo Baldassarre
  • Sulfamide linker, conjugates thereof, and methods of preparation
    Patent number: 10792369
    Abstract: The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Q1 capable of reacting with a functional group F1 present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof: Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q1 of a linker-conjugate according to the invention with a functional group F1 of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: October 6, 2020
    Assignee: SYNAFFIX B.V.
    Inventors: Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Petrus Josephus Jacobus Maria Van De Sande, Sander Sebastiaan Van Berkel, Floris Louis Van Delft
  • Antibody-drug conjugate
    Patent number: 10792370
    Abstract: The present invention relates to an antibody-drug conjugate, in particular, to an antibody-drug conjugate targeting an epidermal growth factor receptor. The present invention also relates to a composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate in manufacture of a medicament for the prophylaxis and/or treatment of a disease associated with epidermal growth factor receptor, in particular in manufacture of a medicament for prophylaxis and/or treatment of colon cancer, rectal cancer, head and neck cancer, lung cancer, ovarian cancer, cervical cancer, bladder cancer and esophageal cancer. The antibody-drug conjugate of the invention has a good inhibition activity on tumor cell growth both in vivo and in vitro, and has low toxicity, and thus has a good application prospect.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: October 6, 2020
    Assignee: SHANGHAI MIRACOGEN INC
    Inventor: Chaohong Hu